newsActimab-A CLAG-M combination displays 100 percent remission rate4 November 2021 | By Anna Begley (European Pharmaceutical Review)Actinium's Actimab-A CLAG-M combination showed a 100 percent remission rate in relapsed or refractory acute myeloid leukaemia patients receiving 0.75 μCi/kg in Phase I study.
newsFDA grants orphan drug designation to Iomab-B31 March 2016 | By Victoria WhiteActinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant...